Explore

Rapid Read Rapid Read
Scientists Develop New Drug to Target 'Undruggable' Pancreatic Cancer, Doubling Survival Rates

Scientists Develop New Drug to Target 'Undruggable' Pancreatic Cancer, Doubling Survival Rates

Researchers have made a significant breakthrough in the treatment of pancreatic cancer, a disease known for its low survival rates. A new drug, daraxonrasib, has been developed to target the KRAS gene mutation, which is responsible for over 90% of pancreatic tumors. This mutation causes the KRAS protein to remain in a constant 'on' state, leading to uncontrolled cell growth. Historically, KRAS has been considered 'undruggable' due to its smooth surface, which lacks binding sites for drugs. However, daraxonrasib works by binding to cyclophilin A, a molecule that assists in protein folding, thereby inhibiting KRAS activity. In a Phase 3 clinical trial involving 500 patients with metastatic pancreatic cancer, daraxonrasib nearly doubled the median survival time from 6.7 to 13.2 months compared to standard chemotherapy. The drug also reduced the risk of death by 60%. Common side effects include skin rash, stomatitis, and gastrointestinal issues, but these are less severe than those associated with chemotherapy...
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Garners Applause at ASCO for Doubling Survival Rates

Revolution Medicines' Pancreatic Cancer Drug Garners Applause at ASCO for Doubling Survival Rates

Revolution Medicines' Pancreatic Cancer Drug Garners Applause at ASCO for Doubling Survival Rates
Trendline Trendline
Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013
Rapid Read Rapid Read
Servier Presents Promising Phase 1 Data for Emiltatug Ledadotin in Adenoid Cystic Carcinoma

Servier Presents Promising Phase 1 Data for Emiltatug Ledadotin in Adenoid Cystic Carcinoma

Servier has announced encouraging Phase 1 clinical trial results for Emiltatug Ledadotin (Emi-Le), an investigational antibody drug conjugate (ADC) targeting B7-H4, at the ASCO 2026 Annual Meeting. The trial involved 180 patients with advanced or metastatic solid tumors, including 48 with adenoid cystic carcinoma (ACC). Emi-Le demonstrated a favorable safety profile and promising efficacy, with a 35.6% objective response rate and an 82.2% disease control rate among ACC patients. The U.S. FDA has granted Breakthrough Designation to Emi-Le for treating locally advanced, recurrent, or metastatic ACC, highlighting the critical need for targeted therapies in this patient population.
Rapid Read Rapid Read
Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

An experimental drug, daraxonrasib, has shown promising results in a Phase 3 clinical trial for patients with metastatic pancreatic cancer. The trial, which enrolled 500 patients, revealed that those treated with daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. The drug, designed to block RAS proteins, reduced the risk of death by 60%. These findings were presented at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine.
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Trendline Trendline
Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.
Rapid Read Rapid Read
Sumitomo Pharma America Reveals Promising Clinical Data for SMP-3124LP at ASCO 2026

Sumitomo Pharma America Reveals Promising Clinical Data for SMP-3124LP at ASCO 2026

Sumitomo Pharma America, Inc. (SMPA) has presented clinical data from its first-in-human Phase 1/2 trial of SMP-3124LP, a selective checkpoint kinase 1 (CHK1) inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The investigational drug, delivered via a PEGylated liposome formulation, is designed to treat malignancies with high replication stress. The trial enrolled 61 patients with advanced solid tumors, showing a 48.2% disease control rate and five partial responses. The drug was generally well-tolerated, with manageable safety profiles, and no dose-limiting toxicities were observed at lower doses.
Rapid Read Rapid Read
Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's Drug Extends Survival in Pancreatic Cancer Patients by Nine Months

Immuneering's investigational drug, atebimetinib, has shown promising results in a Phase 2a trial for pancreatic cancer, extending median overall survival by nearly nine months compared to standard treatments. The drug, combined with modified gemcitabine/nab-paclitaxel, demonstrated a median overall survival of 17.3 months. The trial results were presented at the American Society of Clinical Oncology (ASCO) meeting, highlighting the drug's potential as a first-line treatment for metastatic pancreatic cancer.
Trendline Trendline
Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment
Rapid Read Rapid Read
New Studies Highlight Advances in Treatment for Relapsed Blood Cancer

New Studies Highlight Advances in Treatment for Relapsed Blood Cancer

Two significant studies presented at the American Society of Clinical Oncology meeting in Chicago have revealed promising advancements in the treatment of relapsed multiple myeloma, a type of blood cancer. The first study focused on mezigdomide, an oral drug that, when combined with other treatments, significantly improved progression-free survival rates. The second study examined Teclistamab, an immunotherapy that showed a substantial reduction in disease progression and death risk. These studies indicate a shift towards more effective and less burdensome treatment options for patients who have relapsed after initial therapies.